Provided by Tiger Trade Technology Pte. Ltd.

Biogen

215.43
+4.702.23%
Post-market: 217.001.57+0.73%18:05 EDT
Volume:936.62K
Turnover:201.52M
Market Cap:31.81B
PE:38.26
High:216.70
Open:209.92
Low:208.93
Close:210.73
52wk High:225.80
52wk Low:135.39
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.30
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.69
PE(LYR):24.51

Loading ...

RBC says Biogen detailed Phase 2 results ‘leave more questions than answers’

TIPRANKS
·
Jul 14

Biogen to face questions on safety and dose response, says Stifel

TIPRANKS
·
Jul 14

Eisai, Biogen announce presentation of results from real-world LEADER study

TIPRANKS
·
Jul 14

Leqembi® Real-world Leader Study Presented at Aaic® 2026 Finds over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved over an Average of 17 Months of Treatment

THOMSON REUTERS
·
Jul 14

Movement Alert|Biogen Falls 7.06% in Regular Trading, Diranersen Phase 2 CELIA Full Data Reveals Missed Primary Endpoint Sparking Registration Path Concerns

Market Focus
·
Jul 14

Biogen Down over 7%, on Pace for Largest Percent Decrease Since November 2020

Dow Jones
·
Jul 14

Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)

TIPRANKS
·
Jul 14

Biogen Shares Down 6.2% After Co's Experimental Alzheimer's Drug Misses Main Goal in Mid-stage Study

THOMSON REUTERS
·
Jul 14

Biogen announces expanded data from CELIA study evaluating diranersen

TIPRANKS
·
Jul 14

Biogen Plans Phase 3 Development of Alzheimer’s Tau Therapy Diranersen After Phase 2 Data

Reuters
·
Jul 14

Biogen - to Advance Diranersen into Confirmatory Phase 3 Development

THOMSON REUTERS
·
Jul 14

Biogen - Diranersen Shows 50–65% Mean Reduction in Csf Total Tau and Brain Tau Pathology

THOMSON REUTERS
·
Jul 14

Biogen Presents Phase 2 Celia Data at Aaic Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

THOMSON REUTERS
·
Jul 14

Biogen's Alzheimer's Drug Lowers Toxic Protein, but Results were Mixed

Reuters
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
Jul 14

Piper Sandler Remains a Buy on Biogen (BIIB)

TIPRANKS
·
Jul 14

Canaccord Genuity Remains a Buy on Biogen (BIIB)

TIPRANKS
·
Jul 14

IQLIK Approval Seen as Commercial Enhancer, Not Fundamental Shift, as Biogen Neutral Rating and $200 Price Target Remain Unchanged

TIPRANKS
·
Jul 14

Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector?

Simply Wall St.
·
Jul 14

Eisai Inc: Leqembi Iqlik Initiation Dosing Expected to be Available in U.S. Late August 2026

THOMSON REUTERS
·
Jul 14